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Plasma From Patients Undergoing 
Liver Transplantation Is Resistant 
to Anticoagulant Activity of Soluble 
Thrombomodulin
Laura C. Burlage,1,2 Sarah Bos,2 Jelle Adelmeijer,2 Takumi Sakai,3 Robert J. Porte,1 and  
Ton Lisman1,2
1 Section of HPB Surgery and Liver Transplantation; 2 Surgical Research Laboratory, Department of Surgery, University Medical 
Center Groningen, University of Groningen, Groningen, the Netherlands; and 3 Development Planning, Clinical Department 
Center, Asahi Kasei Pharma Corporation, Tokyo, Japan
Recombinant human soluble thrombomodulin (ART-123) is an anticoagulant and anti-inflammatory agent clinically used for 
treatment of disseminated intravascular coagulation. Preclinical studies have shown that ART-123 reduces hepatic ischemia/
reperfusion. Although ART-123 may therefore have clinical benefit in orthotopic liver transplantation, the substantial altera-
tions in the hemostatic system may complicate its use in this setting. Here, we studied the in vitro effect of ART-123 on coagu-
lation of patients with end-stage liver disease undergoing liver transplantation. Ten patients with end-stage liver disease 
undergoing liver transplantation were included in this study. Plasma samples of 10 healthy individuals were included to estab-
lish reference values. Different concentrations of ART-123 were added to plasma samples, and peak thrombin generation and 
clot lysis times (CLTs) were determined. In patient samples, plasma was profoundly resistant to the anticoagulant action of 
ART-123, as reflected by significantly higher median inhibitory concentration (IC50) values of peak thrombin generation com-
pared with controls. This might be partially explained by low levels of protein C, protein S, and elevated levels of factor VIII 
during transplantation. Intraoperative levels of thrombin activatable fibrinolysis inhibitor were significantly lower when com-
pared with controls. However, ART-123–dependent prolongation of CLTs was not significantly different from healthy con-
trols. In conclusion, this study suggests that ART-123 is unlikely to provoke bleeding in patients undergoing liver transplantation 
because proposed clinical dosages have a virtually absent anticoagulant effect in these patients. Clinical studies are required to 
confirm the safety of ART-123 and efficacy on alleviating ischemia/reperfusion injury during liver transplantation.
Liver Transplantation 25 252‒259 2019 AASLD.
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Orthotopic liver transplantation (OLT) remains the 
only treatment option for patients with end-stage liver 
failure, including cirrhosis. Worldwide organ scarcity 
has led to an increased utilization of suboptimal donor 
livers, such as livers from donation after circulatory 
death donors, elderly donors, and fatty livers. These 
extended criteria donor livers are, however, more prone 
to ischemia/reperfusion injury (IRI)–related complica-
tions after transplantation, including graft dysfunction, 
early graft loss, and posttransplant cholangiopathy.(1,2) 
IRI in liver transplantation refers to the deleterious 
biphasic phenomenon of absence of oxygen during 
static cold preservation of the graft and restoration 
of oxygen supply upon reperfusion. The underlying 
mechanisms of ischemia/reperfusion (I/R)–related 
injury to the liver are complex and multifactorial.(3,4)
Recombinant human soluble thrombomodulin 
(ART-123) is a novel drug composed of the active, 
extracellular domain of thrombomodulin (TM). TM is 
a transmembrane glycoprotein ubiquitously expressed 
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on vascular endothelial cells. TM plays a key role in both 
coagulation and inflammation by binding thrombin and 
accelerating the activation of protein C into activated 
protein C (APC).(5) In addition, TM enhances the rate 
of activation of thrombin activatable fibrinolysis inhib-
itor (TAFI), a crucial regulator of clot breakdown, by 
more than 1000-fold.(6) Like membrane-bound TM, 
ART-123 binds to thrombin to inactivate coagula-
tion via activation of protein C.(7) Interestingly, APC 
exhibits important cytoprotective functions, including 
antiapoptotic, anti-inflammatory, and barrier stabili-
zation properties.(8) Furthermore, ART-123 inhibits 
high-mobility group box 1 (HMGB1) by enhancing 
thrombin-mediated proteolytic cleavage of HMGB1 or 
by a direct interaction between ART-123 and HMGB1 
that neutralizes its proinflammatory effects.(9,10)
ART-123 is in clinical development for treatment 
of sepsis and disseminated intravascular coagulation 
(DIC).(11,12) ART-123 has been approved for clinical 
use in Japan in 2008, and safety and efficacy in patients 
with sepsis and DIC has been demonstrated in a global 
phase 2 study.(11) Currently, a phase 3 study is ongoing to 
examine safety and efficacy in patients with severe sepsis 
and coagulopathy (clinicaltrials.gov, NCT01598831). In 
addition, a phase 3 study on the use of ART-123 for 
the treatment of acute exacerbation of idiopathic pul-
monary fibrosis (NCT02739165) and a phase 2 study on 
the use of ART-123 for the prevention of cancer treat-
ment–related symptoms such as chemotherapy-induced 
peripheral neuropathy(13) in patients with postoperative 
stage II/III colon cancer (NCT02792842) are ongoing.
Over the last years, evidence from animal experi-
ments is emerging that ART-123 has important organ 
protective effects and that it has cytoprotective effects 
on the endothelium.(14,15) In a rodent model of hepatic 
warm ischemia, livers that were ex vivo perfused with 
ART-123, after 6 hours of static cold preservation, 
showed significantly improved bile production and 
decreased sinusoidal narrowing compared with con-
trols.(16) Binding of ART-123 to HMGB1, a factor 
closely associated with necrotic cell damage, has been 
suggested as a pathophysiological mechanism, whereby 
ART-123 minimizes IRI. HMGB1 is used as a marker 
of injury in human liver and kidney transplantation, and 
animal studies show that inhibition of HMGB1 with a 
neutralizing antibody significantly decreased liver dam-
age after I/R.(17-20) In fact, rats that were given ART-123 
as an inhibitor of HMGB1 demonstrated less liver injury 
after partial hepatic ischemia followed by reperfusion.(21)
The hemostatic system of patients with end-stage 
liver disease is substantially different from healthy indi-
viduals, and these changes may further aggravate during 
transplantation.(22) In short, the hemostatic profile of a 
transplant recipient is characterized by thrombocytope-
nia, which appears balanced by high plasma levels of the 
von Willebrand factor,(23) reduced plasma levels of both 
procoagulant and anticoagulant proteins,(24) and reduced 
plasma levels of both profibrinolytic and antifibrinolytic 
proteins.(25) During transplantation, there is persistent 
elevation of the von Willebrand factor, a further decline 
in procoagulant and anticoagulant proteins, and a further 
decline in profibrinolytics and antifibrinolytics.(26-28) 
Moreover, we have previously demonstrated that throm-
bin generation in patients undergoing liver transplanta-
tion is equal or even superior to thrombin generation in 
healthy volunteers when tested in the presence of exog-
enous TM.(27) However, these previous studies were 
performed with a soluble form of rabbit TM. For safe 
application of ART-123 in transplant recipients, it is 
of utmost importance to investigate the anticoagulant 
and profibrinolytic effects of ART-123 in plasma taken 
during the transplant procedure. In this study, we aimed 
to study the in vitro effects of ART-123 on coagulation 
and fibrinolysis in samples taken from patients with end-
stage liver disease during and in the first days after OLT.
Patients and Methods
pATIENTs
Ten adult patients previously diagnosed with cirrhosis, 
who underwent OLT at the University Medical Center 
Groningen, University of Groningen, P.O. Box 30.001, 9700 
RB Groningen, the Netherlands. Telephone: + 31 50 3619028; 
FAX: +31 50 3632796; E-mail: j.a.lisman@umcg.nl
This study was financially supported in part by Asahi Kasei Pharma 
Corporation (Tokyo, Japan).
Takumi Sakai is an employee of and has received grants/contracts 
from Asahi Kasei Pharma Corporation. Tom Lisman has received 
grants/contracts from Asahi Kasei Pharma Corporation.
Copyright © 2018 The Authors. Liver Transplantation published 
by Wiley Periodicals, Inc. on behalf of American Association for the 
Study of Liver Diseases. This is an open access article under the terms 
of the Creative Commons Attribution NonCommercial License, which 
permits use, distribution and reproduction in any medium, provided the 
original work is properly cited and is not used for commercial purposes.
View this article online at wileyonlinelibrary.com.
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Groningen, the Netherlands, between December 2015 
and April 2017 were included in the study. Exclusion 
criteria were acute liver failure, documented hered-
itary thrombophilia, a recent deep vein thrombosis 
(<30 days), transfusion of blood products in the past 
7 days, and current use of anticoagulant drugs. After 
transplantation, all patients received a standard im-
munosuppression regimen consisting of basiliximab, 
prednisolone, mycophenolate mofetil (CellCept), and 
tacrolimus (PROGRAFT). Moreover, after trans-
plantation all patients received standard thrombo-
sis prophylaxis with low-molecular-weight heparin 
(Nadoparin 2850 IE/day via a subcutaneous injection). 
Individual plasma samples of 10 adult healthy volun-
teers working at our institution were used to estab-
lish reference values. Exclusion criteria for the control 
group were documented hereditary thrombophilia, a 
documented history of a recent deep vein thrombosis 
(<30 days), transfusion of blood products in the past 
7 days, and current usage of anticoagulant drugs. 
The study protocol was approved by the medical 
ethical committee of the University Medical Center 
Groningen (METc2015.206). Written informed con-
sent was obtained from all patients in this study prior 
to inclusion.
ETHICs sTATEMENT
The study protocol was approved by the medical 
ethical committee of the University Medical Center 
Groningen (METc2015.206). Written informed con-
sent was obtained from patients all in this study prior 
to inclusion.
pLAsMA sAMpLEs
Blood samples from patients were collected during and 
after liver transplantation in a single-center setting at 7 
predefined time points:
1. 30 minutes after induction of anesthesia.
2. 30 minutes after the start of the anhepatic phase.
3. 30 minutes after graft reperfusion.
4. At the end of surgery.
5. 24 hours after transplantation.
6. 3 days after transplantation.
7. 6 days after transplantation.
Intraoperative blood samples were taken from a 
dedicated nonheparinized arterial line while samples 
on the postoperative days (PODs) and from controls 
were drawn by venapuncture. Blood samples from all 
patients were collected in tubes containing 3.2% so-
dium citrate (9:1, vol/vol). Platelet-poor plasma was 
obtained by centrifuging blood samples at 18°C for 
10 minutes at 2000g and subsequently for 10 minutes 
at 10,000g within 30 minutes after blood collection. 
Plasma samples were stored at –80°C until use.
AssAYs
Peak Thrombin Generation
Peak thrombin generation capacity was assessed 
with calibrated automated thrombography (CAT) 
using platelet-poor plasma, as previously described 
by Hemker et al.(29) In short, the CAT method en-
ables the quantification of thrombin generation 
capacity in an individual sample after induction 
of coagulation by using a f luorescent substrate. 
Fluorescence was continuously measured by a f luoro-
meter, Fluoroskan Ascent (ThermoFisher Scientific, 
Helsinki, Finland). All procedures were according 
to the protocol suggested by Thrombinoscope BV 
(Maastricht, the Netherlands). Peak thrombin gen-
eration capacities were determined in the absence 
and presence of different concentrations of ART-123 
(0, 0.03, 0.3, 3, 30, and 300 μg/mL), and median 
inhibitory concentration (IC50) values were deter-
mined. The IC50 values represent the concentration 
of ART-123 that is required to inhibit 50% of the 
peak thrombin generation in vitro.
Clot Lysis Assay
Clot lysis assays were performed as described previ-
ously.(30) In short, clot formation was induced by add-
ing a 50-μL mixture of phospholipid vesicles, tissue 
plasminogen activator, tissue factor, and CaCl2 di-
luted in 4-(2-hydroxyethyl)-1-piperazine ethanesul-
fonic acid–buffered saline, to 50 μL of each sample. 
A clot lysis profile was generated by analyzing the 
optical density at 405 nm every 20 seconds in a ki-
netic microplate reader. The clot lysis time (CLT) was 
derived from this clot lysis profile and is defined as 
the time from maximum turbidity to clear transition. 
CLTs were determined in the absence or presence of 
different concentrations of ART-123 (0, 0.03, 0.1, 
0.3, and 1 μg/mL), and IC50 values were determined. 
The IC50 value represents the concentration of ART-
123 that is required for half-maximal prolongation of 
the CLT.
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Protein C, Protein S, Factor VIII, and 
TAFI
Plasma levels of protein C, protein S, and factor VIII 
(FVIII) were determined on an automated coagu-
lation analyzer (ACL 300 TOP) with reagents and 
protocols from the manufacturer (Werfen, Breda, the 
Netherlands). Plasma TAFI levels were determined 
by a commercially available enzyme-linked immu-
nosorbent assay (Zymutest activatable TAFI, Nodia, 
Amsterdam, the Netherlands).
sTATIsTICAL ANALYsIs
Continuous data are presented as means with standard 
deviations (SDs) or medians with interquartile ranges 
as appropriate. Categorical variables are presented as 
numbers with percentages. Differences in IC50 values 
between controls and patients at multiple time points 
were examined using the Kruskal-Wallis test followed 
by the Dunn’s post test. P values of 0.05 or less were 
considered statistically significant. Statistical analyses 
were performed with GraphPad Prism (San Diego, 




Ten patients with cirrhosis were included in this 
study. The main demographic and clinical character-
istics of the study population are shown in Table 1. 
Furthermore, 10 healthy patients, referred to as con-
trols, were included to establish reference values for the 
coagulation tests.
pOsTTRANspLANT OuTCOME
Six-month and 1-year graft and patient survival rates 
were 100% (10 out of 10). Delayed graft function, pri-
mary nonfunction, and thrombosis were not observed 
in this study.
INHIBITION OF THROMBIN 
GENERATION
Thrombin generation tests were performed in plate-
let-poor plasma wherein thrombin formation was 
initiated by tissue factor. The IC50 values were deter-
mined for peak thrombin generation by fitting ART-
123 concentration versus peak thrombin curves by 1 
phase exponential decay curves. In a number of sam-
ples, particularly in samples taken during surgery, the 
inhibitory effect of ART-123 on peak thrombin gen-
eration was too low to obtain curve fits using 1 phase 
exponential decay. In these samples, we therefore esti-
mated IC50 values by using linear regression. Figure 1A 
shows peak thrombin IC50 values for the various time 
TABLE 1. Clinical Characteristics of 10 patients Who 
underwent OLT
Characteristics Numbers
Age, years 58.2 ± 7.6









Proton-pump inhibitor 7 (70)
Beta-blocker 5 (50)
Diuretic (thiazide, loop or 
potassium-sparing)
7 (70)
Rifaximin or lactulose 5 (50)
Ursodeoxycholic acid 3 (30)
Ferrous fumarate 2 (20)
Insulin 2 (20)
Prednisone 1 (10)
Prophylactic antibiotics* 4 (40)
MELD 13 ± 7
INR 1.2 ± 0.1
Prothrombin time, seconds 13 ± 2
Activated partial thromboplastin time, 
seconds
30 ± 4
Fibrinogen, g/L 2.6 ± 1.1
Creatinine, μmol/L 75 ± 30
Platelet count, 109/L 123 ± 34
BMI, kg/m2 25.9 ± 4.6
Ascites, mild 4 (40)
Encephalopathy, mild 3 (30)
NOTE: Numbers are either represented as means ± SD or n 
(%). One patient had cirrhosis based on ASH combined with 
hepatitis C.
*Prophylactic antibiotics were given to 4 patients with spontane-
ous bacterial peritonitis.
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FIG. 1. Overview of analyses in platelet-poor plasma samples of 10 patients and 10 healthy controls. Samples were collected at the start 
of OLT, during the anhepatic phase, after reperfusion, and at the end of the procedure. Moreover, samples were collected during POD 
1 as well as PODs 3 and 6. IC50 values were determined by adding different concentrations of ART-123 (A and B). Plasma levels of 
protein C, free protein S, FVIII, and TAFI were determined in all plasma samples and are depicted as a percentage of normal pooled 
plasma samples (set at 100%) (C-F). All values during different time points in patient plasma samples were compared with values in 
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points examined. Compared with peak thrombin IC50 
values in plasma of healthy controls, IC50 values in pa-
tients were significantly increased at the start of sur-
gery, indicating resistance to the anticoagulant action 
of ART-123. Resistance against ART-123 anticoagu-
lant activity increased during surgery. Compared with 
peak thrombin IC50 values in healthy controls, values 
were significantly higher during the anhepatic phase, 
the reperfusion phase, and at the end of surgery. From 
POD 1 onward, ART-123 sensitivity normalized and 
was comparable with controls at day 6.
INHIBITION OF CLOT LYsIs
ART-123 accelerates thrombin-mediated activation 
of TAFI and thereby substantially prolongs plasma 
CLTs. CLTs were determined by a plasma-based clot 
lysis assay after the addition of different concentrations 
of ART-123. We subsequently determined IC50 values 
(Fig. 1B). In general, ART-123 prolonged CLTs to a 
similar extent in patients and controls. In a number of 
samples, no clot lysis occurred within the 3 hours of 
the assay even in the absence of ART-123 (at the end 
of surgery and POD 1). In these cases, no IC50 val-
ues could be calculated. In samples taken during OLT 
and during the PODs, the antifibrinolytic activity of 
ART-123 was comparable to controls.
pROTEIN C LEvELs
Protein C levels were determined in all plasma 
samples (Fig. 1C). At the start of OLT, protein C 
levels were significantly decreased compared with 
healthy controls. During OLT, protein C levels de-
creased further and were significantly decreased at 
all time points compared with levels in heathy con-
trols; during the anhepatic phase, after reperfusion, 
and at the end of surgery, respectively. From POD 
1 onward, protein C levels normalized with values 
comparable to controls on day 6.
pROTEIN s LEvELs
Protein S levels were determined in all plasma samples 
(Fig. 1D). At the start of surgery, median protein S 
levels were lower compared with controls, but this dif-
ference did not reach statistical significance. Protein S 
levels decreased even further during OLT. Protein S 
levels were significantly lower during reperfusion and 
at the end of surgery compared with levels in healthy 
controls. At POD 1, protein S levels were still de-
creased compared with controls, but levels normalized 
from then onward.
FvIII LEvELs
FVIII levels were determined in all plasma samples 
(Fig. 1E). During the start of surgery and during the 
anhepatic phase, median FVIII levels were elevated 
compared with levels in healthy controls, yet the dif-
ferences did not reach significance. Over the course 
of surgery, FVIII levels normalized. During PODs 1, 
3, and 6, FVIII levels were significantly higher com-
pared with levels in healthy controls.
TAFI LEvELs
TAFI levels were determined in all plasma samples 
(Fig. 1F). At the start of surgery, median TAFI levels 
were lower compared with controls, yet this difference 
did not reach statistical significance. TAFI levels de-
creased even further during OLT. TAFI levels were 
significantly decreased during the anhepatic phase, 
during reperfusion, and at the end of surgery com-
pared with levels in healthy controls. From POD 1 on-
ward, TAFI levels normalized with values comparable 
to controls on day 3.
Discussion
This study shows that plasma of patients undergo-
ing OLT is extremely resistant to the anticoagulant 
activity of ART-123. The resistance of ART-123, as 
shown by elevated peak thrombin IC50 values, was sig-
nificantly higher in the plasma of patients undergoing 
liver transplantation at the start of surgery, during the 
anhepatic phase, after reperfusion, and at the end of 
surgery compared with healthy controls. These results 
are in line with our previously published data showing 
resistance to rabbit-derived TM in similar samples.(27) 
We expanded our previous studies by now testing a 
compound that is in clinical development, and we as-
sessed the effects of multiple doses in order to obtain 
IC50 values.
For effective clinical treatment of DIC, the plasma 
concentration of ART-123 is less than 2 μg/mL, 
although it has been suggested that, based on in vivo 
studies with nonhuman primates, plasma levels of 
ART-123 above 10 μg/mL might increase the risk 
of bleeding in humans.(31) Clinical treatment levels 
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of ART-123 to ameliorate IRI during liver transplan-
tation have yet to be established, but a dose similar 
to that used in the treatment of DIC appears plau-
sible based on the proposed mode of action. At such 
plasma concentrations, clinical application of ART-
123 during liver transplantation is unlikely to provoke 
a clinically significant anticoagulant effect as peak 
thrombin IC50 values are far above the expected plasma 
concentrations of the drug in vivo. With respect to 
bleeding, this dose may therefore be much safer in the 
transplant recipient than in an individual with ade-
quate liver function. The resistance of plasma to the 
anticoagulant action of ART-123 during liver trans-
plantation is partly explained by the decreased levels of 
both protein C and protein S. Consequently, a bleed-
ing risk may be present in those transplant recipients 
who have preserved liver function and (near) normal 
levels of protein C and S, for example patients with 
metabolic disorders. Conversely, a bleeding risk may 
be absent at even higher doses of ART-123 in patients 
with exceptionally low plasma levels of protein C and 
S, for example, patients with acute liver failure.(32)
If ART-123 was tested clinically, it might be relevant 
to avoid the use of prothrombin complex concentrates 
during OLT because these concentrates contain appre-
ciable levels of protein C and S, which would increase 
the anticoagulant potency of ART-123 and potentially 
contribute to (paradoxically) increased perioperative 
bleeding. During the postoperative period, the nor-
malization of protein C and protein S levels allowed 
for a more effective ART-123–mediated inhibition of 
thrombin generation. A mild anticoagulant effect of 
ART-123 in the postoperative period may be benefi-
cial to avoid early hepatic artery thrombosis or venous 
thrombotic events.(33)
FVIII is mainly synthesized by hepatic sinusoidal 
endothelial cells and is typically elevated in chronic 
or acute liver failure. Although in this study we 
were unable to detect a significant increase in lev-
els of FVIII at the start of surgery compared with 
levels in controls, elevated FVIII levels might also 
contribute to ART-123 resistance during surgery as 
was previously demonstrated by us in experiments 
with rabbit TM.(27) In our study, FVIII levels fur-
ther normalized during surgery and levels were sig-
nificantly increased compared with levels in healthy 
controls during the PODs, which may be related to 
persistent elevations in the platelet adhesive protein 
von Willebrand factor,(26) which is a carrier protein 
for FVIII in circulation.
We demonstrated that, in general, ART-123 pro-
longed CLTs, but not in samples in which no clot lysis 
occurred within the 3 hours of the assay (at the end of 
surgery and POD 1). The lack of fibrinolysis at these 
time points has been well described as the postopera-
tive fibrinolytic shutdown.(28,34,35) Moreover, we have 
shown that intraoperative TAFI plasma levels were 
decreased compared with levels in controls. At POD 
1, TAFI levels were already increasing and normalized 
at POD 3 and 6. Interestingly, despite very low intra-
operative TAFI levels, ART-123–mediated inhibition 
of fibrinolysis is still intact as evidenced by the clot 
lysis assay, which is in line with our previously pub-
lished results using rabbit TM.(28) Thus, ART-123 
is expected to exert a balanced antifibrinolytic effect 
during liver transplantation, which is beneficial in pre-
venting excessive blood loss as evidenced by the clini-
cal efficacy of antifibrinolytic agents such as the serine 
protease inhibitor aprotinin.(36)
In conclusion, the thrombin generation capacity in 
plasma of patients undergoing liver transplantation is 
remarkably resistant to the anticoagulant action of ART-
123. During liver transplantation, ART-123 might 
therefore be safely tested as an agent to ameliorate IRI 
via its anti-inflammatory effects as no bleeding diathesis 
is expected to be induced by ART-123 plasma levels of 1 
μg/mL or even higher. Clinical studies are needed to con-
firm the safety profile assessed here in vitro, to determine 
a dosage profile for patients with end-stage liver disease, 
and to assess the efficacy in reducing IRI.
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